Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Qiagen (QGEN) EBITDA (2016 - 2025)

Qiagen's EBITDA history spans 17 years, with the latest figure at $50.9 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 3.77% to $50.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $561.7 million, a 196.84% increase, with the full-year FY2025 number at $659.6 million, up 119.15% from a year prior.
  • EBITDA hit $50.9 million in Q4 2025 for Qiagen, down from $180.1 million in the prior quarter.
  • Over the last five years, EBITDA for QGEN hit a ceiling of $260.1 million in Q1 2022 and a floor of -$175.0 million in Q2 2024.
  • Historically, EBITDA has averaged $118.8 million across 5 years, with a median of $152.9 million in 2023.
  • Biggest five-year swings in EBITDA: crashed 211.8% in 2024 and later soared 197.91% in 2025.
  • Tracing QGEN's EBITDA over 5 years: stood at $94.7 million in 2021, then plummeted by 57.4% to $40.3 million in 2022, then grew by 5.21% to $42.4 million in 2023, then grew by 24.58% to $52.9 million in 2024, then decreased by 3.77% to $50.9 million in 2025.
  • Business Quant data shows EBITDA for QGEN at $50.9 million in Q4 2025, $180.1 million in Q3 2025, and $171.4 million in Q2 2025.